Natera Showcases 35 ASCO Studies, Strengthening Leadership in Oncology Clinical Data
Natera Showcases Expansive Oncology Research Program at ASCO 2026, Highlighting Advances in MRD Testing and Precision Cancer Care Natera announced an extensive oncology research program for the 2026 Annual Meeting…
Vyriad Launches G-Link Platform for Targeted Lentiviral Vector Delivery in T-Cell Therapies
Vyriad has introduced G-Link, a modular platform designed to enhance T-cell targeted lentiviral vector delivery for both in vivo and ex vivo therapeutic applications. Vyriad, Inc. has introduced a new…
InSphero AG Acquires PhenoVista Biosciences, Inc. to Strengthen Advanced 3D Cell-Based Assay Solutions
InSphero AG has acquired PhenoVista Biosciences, Inc. to strengthen its advanced 3D cell-based assay capabilities and expand translational research solutions. InSphero AG has announced the acquisition of PhenoVista Biosciences, Inc.,…
Jupiter Endovascular Reports Positive SPIRARE II Pivotal Trial Results at EuroPCR 2026
Jupiter Endovascular Reports Positive SPIRARE II Pivotal Trial Results at EuroPCR 2026 Jupiter Endovascular, Inc. announced positive topline results from its pivotal SPIRARE II clinical trial evaluating the company’s Vertex™…
Acuitas Therapeutics Highlights In Vivo CAR T Engineering and Ionizable Lipid Quality at 2026 ASGCT Meeting
Acuitas Therapeutics Showcases In Vivo CAR T Engineering and Lipid Innovations at ASGCT 2026 Acuitas Therapeutics concluded a prominent showing at the American Society of Gene & Cell Therapy 2026…
DiaMedica Therapeutics Reaches 75% Enrollment Milestone in Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial
DiaMedica Therapeutics announced that it has reached approximately 75% enrollment in its ReMEDy2 Phase 2/3 acute ischemic stroke trial, marking a key development milestone in the study. DiaMedica Therapeutics Inc.…
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to Board of Directors
CONMED Corporation has appointed Celine Martin and Jeff Mirviss to its Board of Directors, strengthening the company’s leadership and strategic expertise. CONMED Corporation has announced the appointment of two seasoned…
Savara Inc. Highlights Long-Term IMPALA-2 Phase 3 Data for Molgramostim in aPAP
Savara Inc. Reports Sustained Efficacy and Favorable Safety Findings from the Ongoing IMPALA-2 Phase 3 Open-Label Extension Study of Molgramostim in aPAP Patients Savara Inc. announced the presentation of new…
SERI Lugano Launches Global Scientific Initiative Focused on Light-Based Neuroscience and Pineal Gland Research
SERI Lugano Introduces Global Scientific Outreach Program Focused on Light-Based Neuroscience and Pineal Gland Research Switzerland Eye Research Institute, also known as SERI Lugano, has announced the launch of a…
Texas Cancer Institute Adopts Kallisio Technologies Stentra™ as Standard Oral Immobilization Solution
Texas Cancer Institute Implements Kallisio Technologies Stentra™ as Standard-of-Care for Precision Radiation Therapy After Successful Clinical Pilot Kallisio announced that the Texas Cancer Institute has officially transitioned its use of…
Sensome Reports Positive First-in-Human Results for In Situ Lung Cancer Tumor Detection Technology
Sensome Reports Encouraging First-in-Human Clinical Results for Its Innovative In Situ Lung Tumor Detection Technology Sensome has announced positive results from its first-in-human INSPECT clinical study evaluating the company’s microsensor-enabled…
Portal Innovations and NJDEVCO Launch Johnson & Johnson Exchange at HELIX
Portal Innovations and New Brunswick Development Corporation Partner with Johnson & Johnson to Launch the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Strengthening New Jersey’s…